You are here

CymaBay Therapeutics to Participate in Upcoming Investor Conferences

NEWARK, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three upcoming investor conferences: the Piper Jaffray 30th Annual Healthcare Conference, the Evercore ISI HealthCONx Conference, and the BMO Prescriptions for Success Conference.

Piper Jaffray 30th Annual Healthcare Conference  
Date:Tuesday, November 27
Time:12:00pm Eastern Time
Location:Lotte New York Palace Hotel
  
Evercore ISI HealthCONx Conference  
Date:Wednesday, November 28
Time:9:05am Eastern Time
Location:Boston Harbor Hotel
  
BMO Prescriptions for Success Conference 
Date:Wednesday, December 12
Time:11:40am Eastern Time
Location:Mandarin Oriental NYC

To access a live webcast and subsequent archived recording of each presentation, please visit the “Events” section on the CymaBay website at http://ir.cymabay.com/events. 

About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof-of-concept in PBC. CymaBay is currently conducting a Phase 3 study of seladelpar for PBC and a Phase 2b study of seladelpar for NASH.

For additional information about CymaBay visit www.cymabay.com.

Contact:
Hans Vitzthum
LifeSci Advisors, LLC
617-535-7743
Hans@LifeSciAdvisors.com

Tuesday, November 20, 2018 - 08:00